Share

November 2022; 9 (6) Research ArticleOpen Access

Combined Regulatory T-Lymphocyte and IL-2 Treatment Is Safe, Tolerable, and Biologically Active for 1 Year in Persons With Amyotrophic Lateral Sclerosis

Jason R. Thonhoff, James D. Berry, Eric A. Macklin, David R. Beers, Patricia A. Mendoza, Weihua Zhao, Aaron D. Thome, Fabio Triolo, James J. Moon, Sabrina Paganoni, Merit Cudkowicz, Stanley H. Appel
First published August 29, 2022, DOI: https://doi.org/10.1212/NXI.0000000000200019
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1446

Share

Article Information

vol. 9 no. 6 e200019
DOI: 
https://doi.org/10.1212/NXI.0000000000200019
PubMed: 
36038262
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received January 26, 2022
  • Accepted in final form June 14, 2022
  • First Published August 29, 2022.
Copyright & Usage: 
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Jason R. Thonhoff, MD, PhD,
    2. James D. Berry, MD,
    3. Eric A. Macklin, PhD,
    4. David R. Beers, PhD,
    5. Patricia A. Mendoza, RN,
    6. Weihua Zhao, MD, PhD,
    7. Aaron D. Thome, PhD,
    8. Fabio Triolo, PhD,
    9. James J. Moon, PhD,
    10. Sabrina Paganoni, MD, PhD,
    11. Merit Cudkowicz, MD and
    12. Stanley H. Appel, MD
  1. Jason R. Thonhoff, MD, PhD,
  2. James D. Berry, MD,
  3. Eric A. Macklin, PhD,
  4. David R. Beers, PhD,
  5. Patricia A. Mendoza, RN,
  6. Weihua Zhao, MD, PhD,
  7. Aaron D. Thome, PhD,
  8. Fabio Triolo, PhD,
  9. James J. Moon, PhD,
  10. Sabrina Paganoni, MD, PhD,
  11. Merit Cudkowicz, MD and
  12. Stanley H. Appel, MD
  1. From the Houston Methodist Neurological Institute (J.R.T., D.R.B., P.A.M., W.Z., A.D.T., S.H.A.), Houston Methodist Hospital Research Institute, Stanley H. Appel Department of Neurology, Houston, TX; Neurological Clinical Research Institute (J.D.B., S.P., M.C.), Healey & AMG Center for ALS, Massachusetts General Hospital, Boston, MA; Biostatistics Center (E.A.M.), Massachusetts General Hospital, Boston, MA; Harvard Medical School (E.A.M.), Boston, MA; Department of Pediatric Surgery (F.T.), McGovern Medical School, UTHealth-The University of Texas Health Science Center at Houston, Houston, TX; and Center for Immunology and Inflammatory Diseases (J.J.M.), Massachusetts General Hospital, Boston, MA; and Harvard Medical School (J.J.M.), Boston, MA.
  1. Correspondence
    Dr. Appel sappel{at}houstonmethodist.org
View Full Text

Article usage

Article usage: August 2022 to August 2023

AbstractFullPdfSource
Aug 2022328654Highwire
Sep 2022951103315Highwire
Oct 202240881159Highwire
Nov 202247484321Highwire
Dec 20223919473Highwire
Jan 20236427387Highwire
Feb 20233032188Highwire
Mar 20235922293Highwire
Apr 20233016148Highwire
May 20232516652Highwire
Jun 20232917542Highwire
Jul 20235214346Highwire
Aug 20234716068Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me